Indaptus Therapeutics, Inc. (INDP) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -14.77M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 5.22M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-14.77M | (m) | (m) | $5.22M | (m) | (m) |
| 2026-03-31 | $-17.42M | (m) | (m) | $7.02M | (m) | (m) |
| 2025-12-31 | $-19.83M | (m) | (m) | $9.34M | (m) | (m) |
| 2025-09-30 | $-15.85M | (m) | (m) | $8.98M | (m) | (m) |
| 2025-06-30 | $-16.34M | (m) | (m) | $8.92M | (m) | (m) |
| 2025-03-31 | $-16.00M | (m) | (m) | $8.47M | (m) | (m) |
| 2024-12-31 | $-15.37M | (m) | (m) | $7.25M | (m) | (m) |
| 2024-09-30 | $-15.37M | (m) | (m) | $6.81M | (m) | (m) |
| 2024-06-30 | $-16.48M | (m) | (m) | $7.57M | (m) | (m) |
| 2024-03-31 | $-15.87M | (m) | (m) | $7.33M | (m) | (m) |
| 2023-12-31 | $-16.38M | (m) | (m) | $7.62M | (m) | (m) |
| 2023-09-30 | $-16.29M | (m) | (m) | $7.50M | (m) | (m) |
| 2023-06-30 | $-15.59M | (m) | (m) | $6.88M | (m) | (m) |
| 2023-03-31 | $-15.96M | (m) | (m) | $6.91M | (m) | (m) |
| 2022-12-31 | $-14.91M | (m) | (m) | $6.32M | (m) | (m) |
| 2022-09-30 | $-14.04M | (m) | (m) | $5.36M | (m) | (m) |
| 2022-06-30 | $-13.86M | (m) | (m) | $4.45M | (m) | (m) |
| 2022-03-31 | $-10.52M | (m) | (m) | $3.33M | (m) | (m) |
| 2021-12-31 | $-7.73M | (m) | (m) | $2.52M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-3.60M | (m) | (m) | $2.66M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |